SfA (1 μM) treatment did not modulate IPF fibroblast contractility — assessed by αSMA protein levels — or TGF-β1/SMAD signaling (Figure 6, J and K, and Supplemental Figure 11). The gene discussed is ACTA1; the disease is idiopathic pulmonary fibrosis.